Laboratory Corp. of America Holdings (NYSE:LH) CFO Glenn A. Eisenberg Sells 8,400 Shares

Laboratory Corp. of America Holdings (NYSE:LH) CFO Glenn A. Eisenberg sold 8,400 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $167.36, for a total transaction of $1,405,824.00. Following the sale, the chief financial officer now owns 15,931 shares of the company’s stock, valued at $2,666,212.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Laboratory Corp. of America Holdings (LH) traded down $0.65 during trading hours on Wednesday, hitting $173.76. 428,959 shares of the stock were exchanged, compared to its average volume of 657,210. Laboratory Corp. of America Holdings has a 12 month low of $134.19 and a 12 month high of $181.71. The company has a market capitalization of $18,099.02, a price-to-earnings ratio of 14.33, a price-to-earnings-growth ratio of 1.50 and a beta of 0.93. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.20 and a current ratio of 1.31.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $2.45 EPS for the quarter, beating the Zacks’ consensus estimate of $2.38 by $0.07. Laboratory Corp. of America had a net margin of 12.15% and a return on equity of 16.30%. The company had revenue of $2.70 billion for the quarter, compared to analyst estimates of $2.70 billion. During the same quarter last year, the firm posted $2.15 earnings per share. The company’s quarterly revenue was up 13.2% compared to the same quarter last year. research analysts expect that Laboratory Corp. of America Holdings will post 11.52 EPS for the current fiscal year.

Several equities analysts recently weighed in on the stock. ValuEngine lowered shares of Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Zacks Investment Research raised shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Craig Hallum reaffirmed a “buy” rating and set a $204.00 price objective (up previously from $180.00) on shares of Laboratory Corp. of America in a research report on Wednesday, February 7th. Barclays raised their price objective on shares of Laboratory Corp. of America from $183.00 to $190.00 and gave the company an “overweight” rating in a research report on Thursday, October 26th. Finally, Mizuho set a $165.00 price objective on shares of Laboratory Corp. of America and gave the company a “neutral” rating in a research report on Friday, December 1st. Six equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. Laboratory Corp. of America has a consensus rating of “Buy” and a consensus price target of $180.73.

Several large investors have recently added to or reduced their stakes in the company. Zions Bancorporation grew its stake in shares of Laboratory Corp. of America by 7,444.4% in the third quarter. Zions Bancorporation now owns 679 shares of the medical research company’s stock worth $103,000 after acquiring an additional 670 shares during the last quarter. Financial Gravity Companies Inc. acquired a new stake in shares of Laboratory Corp. of America in the fourth quarter worth $182,000. Calton & Associates Inc. acquired a new stake in shares of Laboratory Corp. of America in the fourth quarter worth $213,000. Weik Capital Management acquired a new stake in shares of Laboratory Corp. of America in the fourth quarter worth $200,000. Finally, Hourglass Capital LLC acquired a new stake in shares of Laboratory Corp. of America in the fourth quarter worth $207,000. 90.41% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Laboratory Corp. of America Holdings (NYSE:LH) CFO Glenn A. Eisenberg Sells 8,400 Shares” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/21/glenn-a-eisenberg-sells-8400-shares-of-laboratory-corp-of-america-holdings-lh-stock.html.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply